Needham: 'we believe that IMDX is making good progress towards its GraftAssureDx submissions'
Tweet Send to a Friend
Needham analyst Mike Matson reiterated a Buy rating and $9.00 price target on Insight Molecular Diagnostics Inc. (NASDAQ: IMDX).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
